// App-Quantinova.ai

P672 : Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn’s disease studies, by population

Researchers

Presenter

  • S Ghosh

Principal Investigators

  • C Gasink

  • L -L Gao

  • C Obando

Medical Centers

  • University of Birmingham, Birmingham, United Kingdom

  • Janssen Scientific Affairs, Horsham, PA

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved